Table 1.
The clinical and sociodemographic characteristics of the two populations included in this study, REGISPONSER and RESPONDIA, in patients with ankylosing spondylitis.
| RESPONDIA N = 1254 |
REGISPONSER N = 1512 |
p-Value | |
|---|---|---|---|
| Sex (male) | 916 (73.0%) | 1130 (74.7%) | 0.314 |
| Age | 44.3 (16.2) | 48.1 (12.8) | <0.001 |
| Age at diagnosis | 36.4 (15.6) | 34.8 (11.9) | 0.007 |
| Time since symptoms onset | 14.8 (11.6) | 21.0 (13.1) | <0.001 |
| Time since diagnosis | 7.3 (8.4) | 13.2 (10.4) | <0.001 |
| Diagnosis delay | 6.9 (8.9) | 7.7 (9.3) | 0.033 |
| BMI | 25.9 (4.5) | 26.7 (4.4) | <0.001 |
| HLA-B27 positive | 459/647 (70.9%) | 1114/1352 (82.4%) | <0.001 |
| Family history of SpA | 228/1228 (18.6%) | 285/1402 (20.3%) | 0.255 |
| Inflammatory back pain | 1196/1251 (95.6%) | 1474 (97.5%) | 0.008 |
| Alternating buttock pain | 693/1252 (55.4%) | 965/1492 (64.7%) | <0.001 |
| Arthritis ever | 696/1252 (55.6%) | 511/1508 (33.9%) | <0.001 |
| Enthesitis ever | 664/1244 (53.4%) | 461/1501 (30.7%) | <0.001 |
| Dactylitis ever | 155/1248 (12.4%) | 83/1506 (5.5%) | <0.001 |
| Cutaneous psoriasis | 138/1249 (11.0%) | 140/1408 (9.3%) | 0.126 |
| Nail disease | 83/1192 (7.0%) | 45/1507 (3.0%) | <0.001 |
| IBD | 58 (4.6%) | 84 (5.6%) | 0.270 |
| Uveitis | 274/1244 (22.0%) | 321/1502 (21.4%) | 0.678 |
| CRP | 9.7 (18.3) | 8.9 (13.5) | 0.236 |
| BASDAI | 4.4 (2.4) | 4.1 (2.3) | 0.002 |
| ASDAS-CRP | 2.6 (1.2) | 2.6 (1.1) | 0.227 |
| BASRI total | 7.9 (4.2) | 6.9 (4.1) | <0.001 |
| bDMARD ever | 113 (9.0%) | 304 (20.1%) | <0.001 |
| csDMARD ever | 621 (49.5%) | 441 (29.2%) | <0.001 |
Continuous variables are described by their mean and the standard deviation (between brackets), while absolute and percentages are shown for categorical variables.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASRI, Bath Ankylosing Spondylitis Radiology Index; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IBD, inflammatory bowel disease; SPA, spondyloarthritis.